Will radiation capitalise on its lead over drug-coated stents?
This article was originally published in Clinica
Drug-coated stents and intravascular brachytherapy products are set to battle it out for market dominance over the next few years. But radiation devices will have the advantage of reaching the market first. That was the clear view of US Bancorp Piper Jaffray analyst Scott Davidson speaking at his company's annual healthcare conference in New York last month. He went on to predict the main developments and controversies expected during the year.